메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

PharmaResearch Receives U.S. FDA Clearance to Initiate Phase 1 Clinical Trial of Nano Anticancer Drug, PRD-101

SEONGNAM, South Korea, Feb. 6, 2026 -- PharmaResearch Co., Ltd. (CEO: Jihoon Sohn) today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for PRD-101, enabling the initiation of a Phase 1 clinical trial in the United States. PRD-101 is a next-generation nano anticancer drug candidate formulated using nucleotide fragments produced through PharmaResearch's proprietary DOT® (DNA Optimizing Technology). The drug leverages the company's nucleotide-based Advanced DOT™ drug delivery platform, designed to
- 김갑성 기자
- 2026-02-06 15:20
Everest Medicines Announces China NMPA Approval of VELSIPITY® for Adults with Moderately to Severely Active Ulcerative Colitis

SHANGHAI, Feb. 6, 2026 -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that China's National Medical Products Administration (NMPA) has approved VELSIPITY® (etrasimod arginine tablets) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agen
- 김갑성 기자
- 2026-02-06 13:10
Akeso Receives Fifth Breakthrough Therapy Designation from NMPA for Ivonescimab in First-Line Treatment of Advanced Biliary Tract Cancer

HONG KONG, Feb. 6, 2026 -- Akeso, Inc. (9926.HK) is pleased to announce that ivonescimab, its global first-in-class bispecific antibody targeting PD-1 and VEGF, has been granted its fifth Breakthrough Therapy Designation from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). This latest designation applies to ivonescimab in combination with chemotherapy for the first-line treatment of advanced biliary tract cancer (BTC). This milestone represents the fifth BTD awarded to ivonescimab by the NMPA, following three prior designations in lung cance
- 김갑성 기자
- 2026-02-06 10:26
Sky Labs Signs Exclusive Distribution Agreement with Otsuka Pharmaceutical for 'CART BP pro' in Japan

- Secures distribution agreement to launch CART BP pro in the Japanese hospital and clinic market- Leveraging proven technology with adoptions in 1,700+ medical institutions and national health insurance coverage in Korea SEOUL, South Korea, Feb. 6, 2026 -- Sky Labs Inc. (CEO Jack Byunghwan Lee) announced on the 5th that it has entered into an exclusive distribution agreement with Otsuka Pharmaceutical Co., Ltd. (Otsuka) for the ring-type blood pressure monitor, 'CART BP pro', in the Japanese hospital and clinic market. This agreement follows the memorandum
- 김갑성 기자
- 2026-02-06 09:00
Precision for Medicine Broadens Global Footprint with Singapore Office Opening

Singapore Office Expands APAC Presence to Seven Locations, Delivering Enhanced Local Expertise and Global Scale BETHESDA, Md., Feb. 6, 2026 -- Precision for Medicine (Precision), a global leader in biomarker-driven clinical research and development, has announced the opening of a new office in Singapore. This strategic expansion strengthens Precision's significant presence across the Asia-Pacific (APAC) region, serving as a crucial hub for enhanced client support and accelerated regional growth. "This expansion, particularly with our new Singapore hub, signifies a m
- 김갑성 기자
- 2026-02-06 08:50
World's First Serum-Free Iterative Rabies Vaccine from AIM Successfully Passes On-Site Registration Inspections and Is Imminent for Launch

HONG KONG, Feb. 6, 2026 -- Poised to Fill the Global Market Gap, the Serum-Free Iterative Rabies Vaccine Approaches a Critical Milestone in Commercialization. AIM Vaccine (06660.HK), a leading domestic vaccine company, announced on February 5 that its wholly-owned subsidiary AIM Rongyu's world's first independently developed serum-free iterative rabies vaccine has successfully passed the National Medical Products Administration (NMPA) on-site inspection for drug clinical trials and the on-site inspection for drug registration and production. This marks a major step forward for this highly ant
- 김갑성 기자
- 2026-02-06 07:30
VARON Marks Valentine's Day With Health-Focused Savings That Put Care First

Love looks like care. This Valentine's Day, VARON invites families to show love in a way that helps loved ones breathe easier—at home and on the go. NEW YORK, Feb. 6, 2026 -- VARON, a trusted provider of respiratory care solutions, today announced its Valentine's Day Sale, a limited-time event designed to celebrate love through meaningful, health-forward gifts. Centered on comfort, mobility, and peace of mind, the event offers thoughtful savings across VARON's lineup of portable oxygen concentrator and home oxygen concentrator options without losing sight of what matters most:
- 김갑성 기자
- 2026-02-06 07:18
This Valentine's Day, VARON Encourages Filipinos to Show Love Through Better Respiratory Health

MANILA, Philippines, Feb. 5, 2026 -- Valentine's Day is traditionally associated with flowers and chocolates, but health experts encourage Filipinos to also prioritize well-being for themselves and their loved ones. Respiratory health is increasingly important as more people manage chronic conditions, recover from illness, or maintain active lifestyles amid environmental challenges. VARON Philippines marks the occasion by promoting oxygen care as a meaningful way to show love, emphasizing mobility, comfort, and peace of mind. Love and Health: Caring Beyond
- 김갑성 기자
- 2026-02-06 07:11
Field Medical Presents Late Breaking Field PULSE Trial Data at AF Symposium 2026

Demonstrating Instantaneous Ablation Through High-Voltage Waveforms and Efficient Point-by-Point Pulsed Field Ablation CARDIFF-BY-THE-SEA, Calif., Feb. 6, 2026 -- Field Medical, Inc., a clinical-stage medical technology company advancing pulsed field ablation (PFA) solutions for complex cardiac arrhythmias, today announced the presentation of late breaking clinical trial data from the first-in-human Field PULSE study at the 31st Annual International AF Symposium 2026, held February 5–7 in Boston. Field PULSE evaluates a novel high-voltage, sub-second pulsed field
- 황정호 기자
- 2026-02-06 06:40
Piramal Critical Care and Blue-Zone Technologies collaborate to capture, collect and recycle waste anaesthesia gas

MUMBAI, India, Feb. 6, 2026 -- Piramal Critical Care, Inc. (PCC), an overseas subsidiary of Piramal Pharma Limited, and Blue-Zone Technologies Ltd. (Blue-Zone) announced an agreement to collaborate on full lifecycle technology to capture and recycle waste anaesthetic gases. By combining the innovative waste anaesthesia gas capture, collection, and processing technology developed by Blue-Zone, with the global manufacturing and marketing capabilities of Piramal, this collaboration will support customers' efforts to minimize the environmental impact of volatile anaesthetics. This
- 김갑성 기자
- 2026-02-06 01:04

이전

11 12 13 14 15 16 17 18 19 20

많이 본 기사

최근기사

2026-03-02_MON

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 03월 03일 01시 00분